Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer;Resultados del uso expandido del PCA3 score en una población española con sospecha de cáncer de próstata

Actas Urologicas Espanolas

Volumn 35, Issue 10, 2011, Pages 589-596

  Rubio Briones, J ^a   Fernandez Serra A ^a   Ramirez M ^a   Rubio, L ^a   Collado, A ^a   Casanova, J ^a   Gomez Ferrer A ^a   Ricos J V ^a   Monros J L ^a   Dumont, R ^a   Ortiz, B ^a   Iborra, I ^a   Garcia Casado Z ^a   Solsona, E ^a   Lopez Guerrero J A ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

PCA3 score; Prediction; Prostate cancer; Prostatic biopsy; PSA

Indexed keywords

MESSENGER RNA; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ANALYTICAL EQUIPMENT; ARTICLE; GENETICS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPAIN; URINE; UTILIZATION REVIEW;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RNA, MESSENGER; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPAIN; TUMOR MARKERS, BIOLOGICAL;

EID: 80054685555     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2011.04.001     Document Type: Article

References (30)

1. F.H. Schroder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, and V. Nelen Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
2. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd, S.S. Buys, D. Chia, and T.R. Church Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
3. J. Hugosson, S. Carlsson, G. Aus, S. Bergdahl, A. Khatami, and P. Lodding Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
4. G. Draisma, R. Boer, S.J. Otto, I.W. van der Cruijsen, R.A. Damhuis, and F.H. Schroder Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878 (Pubitemid 36833878)
5. I.M. Thompson, D.K. Pauler, P.J. Goodman, C.M. Tangen, M.S. Lucia, and H.L. Parnes Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter N Engl J Med 350 2004 2239 2246
6. R. Postma, and F.H. Schroder Screening for prostate cancer Eur J Cancer 41 2005 825 833 (Pubitemid 40461688)
7. M.J. Bussemakers, A. van Bokhoven, G.W. Verhaegh, F.P. Smit, H.F. Karthaus, and J.A. Schalken DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979 (Pubitemid 30004960)
8. J. Ruiz-Aragón, and S. Márquez-Peláez Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis Actas Urol Esp 34 2010 346 355
9. R. Wang, A.M. Chinnaiyan, R.L. Dunn, K.J. Wojno, and J.T. Wei Rational approach to implementation of prostate cancer antigen 3 into clinical care Cancer 115 2009 3879 3886
10. L.S. Marks, Y. Fradet, I.L. Deras, A. Blase, J. Mathis, and S.M. Aubin PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532 535 (Pubitemid 46428401)
11. A. Haese, A. de la Taille, H. van Poppel, M. Marberger, A. Stenzl, and P.F. Mulders Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081 1088
12. L.J. Sokoll, W. Ellis, P. Lange, J. Noteboom, D.J. Elliott, and I.L. Deras A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy Clin Chim Acta 389 2008 1 6
13. I.L. Deras, S.M. Aubin, A. Blase, J.R. Day, S. Koo, and A.W. Partin PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587 1592
14. S.M. Aubin, J. Reid, M.J. Sarno, A. Blase, J. Aussie, and H. Rittenhouse PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial J Urol 184 2010 1947 1952
15. G. Ploussard, A. Haese, H. Van Poppel, M. Marberger, A. Stenzl, and P.F. Mulders The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 106 2010 1143 1147
16. S.B. Shappell, J. Fulmer, D. Arguello, B.S. Wright, J.R. Oppenheimer, and M.J. Putzi PCA3 urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting Urology 73 2009 363 368
17. F.K. Chun, A. de la Taille, H. van Poppel, M. Marberger, A. Stenzl, and P.F. Mulders Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659 667
18. D. Hessels, M.P. van Gils, O. van Hooij, S.A. Jannink, J.A. Witjes, and G.W. Verhaegh Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer Prostate 70 2010 10 16
19. H. Nakanishi, J. Groskopf, H.A. Fritsche, V. Bhadkamkar, A. Blase, and S.V. Kumar PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804 1809 discussion 9-10
20. M. Auprich, F.K. Chun, J.F. Ward, K. Pummer, R. Babaian, and H. Augustin Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol 59 2011 96 105
21. V. Vlaeminck-Guillem, M. Devonec, M. Colombel, C. Rodriguez-Lafrasse, M. Decaussin-Petrucci, and A. Ruffion Urinary PCA3 Score Predicts Prostate Cancer Multifocality J Urol 185 2011 1234 1239
22. G. Ploussard, X. Durand, E. Xylinas, S. Moutereau, C. Radulescu, and A. Forgue Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance Eur Urol 59 2011 422 429
23. M. Nyberg, D. Ulmert, A. Lindgren, U. Lindstrom, P.A. Abrahamsson, and A. Bjartell PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population Scand J Urol Nephrol 44 2010 378 383
24. D. Schilling, J. Hennenlotter, M. Munz, U. Bokeler, K.D. Sievert, and A. Stenzl Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice Urol Int 85 2010 159 165
25. S. Perdona, V. Cavadas, G. Di Lorenzo, R. Damiano, G. Chiappetta, and P. Del Prete Prostate Cancer Detection in the "Grey Area" of Prostate-Specific Antigen Below 10 ng/ml: Head-to-Head Comparison of the Updated PCPT Calculator and Chun's Nomogram, Two Risk Estimators Incorporating Prostate Cancer Antigen 3 Eur Urol 59 2011 81 87
26. B. Laxman, D.S. Morris, J. Yu, J. Siddiqui, J. Cao, and R. Mehra A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer Cancer Res 68 2008 645 649 (Pubitemid 351206738)
27. M. Rigau, J. Morote, M.C. Mir, C. Ballesteros, I. Ortega, and A. Sánchez PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine Prostate 70 2010 1760 1767
28. D. Hessels, F.P. Smit, G.W. Verhaegh, J.A. Witjes, E.B. Cornel, and J.A. Schalken Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer Clin Cancer Res 13 2007 5103 5108 (Pubitemid 47502077)
29. J. Rubio-Briones, A. Fernández-Serra, A. Calatrava, Z. García-Casado, L. Rubio, and M.A. Bonillo Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy J Urol 183 2010 2054 2061
30. M.J. Roobol, F.H. Schroder, P. van Leeuwen, T. Wolters, R.C. van den Bergh, and G.J. van Leenders Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481